- ￥1590 - 6000
- MedChemExpress(MCE)
- 美国
- HY-108818
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥3438.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥1590.0 |
| 规格： | 5 mg | 产品价格： | ￥3500.0 |
| 规格： | 10 mg | 产品价格： | ￥6000.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
XZ426
CAS No. : 1638504-52-5
MCE 国际站：XZ426
产品活性：XZ426 是一种有效的整合酶链转移抑制剂，具有抗 HIV 活性。
研究领域：Metabolic Enzyme/Protease
作用靶点：HIV Integrase
In Vitro: Intasomes are the target of the latest generation of antiretroviral drugs, integrase (IN) strand transfer inhibitors (INSTI). To better understand how INSTIs interact with HIV intasomes, we assembled the complex with bictegravir (BIC), the leading second-generation INSTI and the most broadly effective of all clinically approved INSTIs. Among these, XZ426 is a lead candidate that has shown superior efficacy to all clinically used and developed compounds against known drug-resistant variants.
相关产品：Bioactive Compound Library Plus | Anti-Infection Compound Library | Metabolism/Protease Compound Library | Dolutegravir | Bictegravir | Raltegravir | Elvitegravir | Cabotegravir sodium | HIV-1 integrase inhibitor | L-Chicoric Acid | BI 224436 | BMS-707035 | Salicylanilide | (±)-BI-D | Equisetin | Robinetin | HIV-1 integrase inhibitor 3 | HIV-1 integrase inhibitor 4 | Lavendustin B | MK-2048 | (S)-BI-1001 | BDM-2 | Bis-T-23 | Cabotegravir-d5 | Dihydroobionin B
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验analysis and integration: of steps and arrows. Nat Genet, 22(3): 213-5. 17• Boguski MS. 1998. Data management and analysis for gene expression arrays. Nat. Genet., 20:1923. 18• Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C
_307_b 2,453 444 −4.52*** 4,188 443 −8.45*** 3,669 407 −8.01*** 3,318 448 −6.41*** hsa-miR-34c 2,292 412 −4.56** 3,303 426 −6.75*** 3,524 381 −8.25*** 2,403 404 −4.95** hsa-miR-133a 9,270 1,594
%, and was 52.38% in patients with recurrence, the longest remission period was more than ten years, and intravenous route of administration was the choice, no toxic or adverse effects were seen[2-4]. There was no cross resistanc e between arsenic trioxide
技术资料暂无技术资料 索取技术资料
